8-K: BioMarin Q3 2025: Revenue Up, ROCTAVIAN Divestment

BioMarin reports increased Q3 2025 revenues driven by VOXZOGO and PALYNZIQ, raises full-year guidance midpoint, and announces plans to divest ROCTAVIAN.

Summary

• Total Revenues for the third quarter of 2025 were $776 million, an increase of 4% compared to the same period in 2024.
• Year-to-date Total Revenues increased 11% year-over-year (Y/Y) to $2,347 million.
• GAAP Net Loss for Q3 2025 was $31 million, compared to GAAP Net Income of $106 million for Q3 2024, primarily due to a $221 million In-Process Research & Development (IPR&D) charge from the Inozyme Pharma acquisition.
• Non-GAAP Income for Q3 2025 decreased to $22 million compared to $178 million for Q3 2024.
• VOXZOGO revenue increased 15% Y/Y to $218 million in Q3 2025 and 24% Y/Y to $654 million year-to-date.
• PALYNZIQ revenue increased 20% Y/Y to $109 million in Q3 2025 and 21% Y/Y to $308 million year-to-date.
• BioMarin announced plans to pursue options to divest ROCTAVIAN, including out-licensing opportunities, while continuing commercial availability in the U.S., Italy, and Germany until next steps are finalized.
• Full-year 2025 Total Revenues guidance was raised at the midpoint to a range of $3,150 million to $3,200 million.
• Full-year 2025 Non-GAAP Operating Margin guidance was revised to 26%-27% (from 33%-34%) due to the IPR&D charge.
• Full-year 2025 Non-GAAP Diluted EPS guidance was revised to $3.50-$3.60 (from $4.40-$4.55) due to the IPR&D charge.
• Operating cash flows totaled $369 million in Q3 2025 and $728 million year-to-date.
• Total cash and investments were approximately $2.0 billion at the end of Q3 2025.

Sentiment

Score: 6

Explanation: While core products VOXZOGO and PALYNZIQ show robust growth and the pipeline is advancing, the substantial IPR&D charge from the Inozyme acquisition resulted in a GAAP net loss and a significant reduction in non-GAAP income and full-year guidance. The decision to divest ROCTAVIAN, while strategic, indicates a commercial challenge for a previously touted gene therapy. The overall sentiment is cautiously optimistic due to underlying product strength but tempered by the immediate financial impact of the acquisition and the ROCTAVIAN decision.

Positives

• Total Revenues increased 4% Y/Y in Q3 2025 and 11% Y/Y year-to-date, demonstrating overall growth.
• VOXZOGO revenue grew 15% Y/Y in Q3 2025 and 24% Y/Y year-to-date, with strong uptake in 55 countries and expected highest Q4 revenue.
• PALYNZIQ achieved its third consecutive quarter of 20%+ Y/Y growth, driven by patient titration and adherence.
• Total Enzyme Therapies revenue grew 8% Y/Y year-to-date.
• Full-year 2025 Total Revenues guidance was raised at the midpoint, reflecting strong demand for therapies.
• Generated strong operating cash flows of $369 million in Q3 2025 and $728 million year-to-date.
• Total cash and investments reached approximately $2.0 billion, supporting future innovation and growth.
• New data for VOXZOGO demonstrated improved spinal morphology in children ages 5 and under, adding to evidence of health benefits beyond growth.
• Advancing pipeline with BMN 333 (Phase 2/3 study initiation in H1 2026), VOXZOGO for hypochondroplasia (pivotal data H1 2026, potential launch 2027), and four new VOXZOGO indications (CANOPY program enrolling, potential registration studies 2027).
• BMN 401 (ENPP1 deficiency) initial pivotal data expected H1 2026, with potential launch in 2027.
• Pursuing approvals for PALYNZIQ in 12to 17-year-olds in the US and Europe, with potential approval in 2026.

Negatives

• GAAP Net Loss of $31 million in Q3 2025, a significant decrease from GAAP Net Income of $106 million in Q3 2024.
• Non-GAAP Income decreased substantially to $22 million in Q3 2025 from $178 million in Q3 2024.
• The GAAP Net Loss and Non-GAAP Income decrease were primarily due to a $221 million In-Process Research & Development (IPR&D) charge from the Inozyme Pharma acquisition.
• Lower sales volume for ALDURAZYME (-24% Y/Y in Q3) due to timing of order fulfillment to Sanofi.
• Lower sales volume for NAGLAZYME (-8% Y/Y in Q3) due to timing of large government orders in Latin America.
• Decision to pursue options to divest ROCTAVIAN, indicating underperformance or strategic misalignment for this gene therapy.
• Slowing uptake of VOXZOGO in older children in the U.S., requiring new initiatives to address.
• Revised full-year 2025 Non-GAAP Operating Margin guidance downwards from 33%-34% to 26%-27%.
• Revised full-year 2025 Non-GAAP Diluted EPS guidance downwards from $4.40-$4.55 to $3.50-$3.60.

Risks

• Success in the commercialization of commercial products.
• Impacts of macroeconomic and other external factors on operations, regulatory uncertainty, tariffs, other trade protection measures, and escalating trade tensions.
• Results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials.
• Ability to successfully manufacture commercial products and product candidates.
• Content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission, and other regulatory authorities concerning each of the described products and product candidates.
• The market for each of these products.
• Actual sales of commercial products.
• Factors detailed in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

BioMarin anticipates sustained financial performance from its Enzyme Therapies and Skeletal Conditions business units, which remain central to its growth strategy. The company plans to initiate dosing of children with achondroplasia in the registration-enabling Phase 2/3 study for BMN 333 in the first half of 2026. VOXZOGO pivotal data for hypochondroplasia is expected in the first half of 2026, with a potential launch in 2027. Four new VOXZOGO indications are under development with potential registration-enabling studies in 2027. For PALYNZIQ, the company is pursuing approvals in 12to 17-year-olds in the U.S. and Europe, with potential approval in 2026. Initial pivotal data for BMN 401 (ENPP1 deficiency) is anticipated in the first half of 2026, with a potential launch in 2027. A clinical update for BMN 351 (Duchenne muscular dystrophy) is expected by year-end. BioMarin aims to expand VOXZOGO access to more than 60 countries by 2027. The company also plans to pursue options to divest ROCTAVIAN, including out-licensing opportunities.

Management Comments

• "We are pleased with the contributions from our Enzyme Therapies and Skeletal Conditions business units to date this year driven by more than 20% revenue growth from PALYNZIQ and VOXZOGO."
• "Our strategic investments in these focused business units are generating strong results, and we anticipate sustained financial performance from each of them."
• "Both Enzyme Therapies and Skeletal Conditions remain central to our growth strategy, in addition to new business development opportunities and our advancing internal pipeline."
• "As we focus on the business units aligned with our strategic priorities, today we are announcing the decision to pursue options to divest ROCTAVIAN and remove it from our portfolio."
• "We continue to believe ROCTAVIAN has an important role to play in the treatment of hemophilia A and are therefore evaluating out-licensing options for this innovative gene therapy."
• "This decision is consistent with BioMarin’s portfolio strategy and offers the most promising opportunity for ensuring continued patient access to ROCTAVIAN."
• "Looking ahead, we will rely on our disciplined strategic focus and proven capabilities to develop and commercialize innovative therapies that generate sustainable value for patients, employees, and shareholders."

Industry Context

BioMarin operates in the specialized and high-growth rare disease biotechnology sector. The strong performance of VOXZOGO (for achondroplasia) and PALYNZIQ (for PKU) highlights the significant unmet medical need and commercial potential within this niche. The decision to divest ROCTAVIAN, a gene therapy for hemophilia A, suggests a strategic re-prioritization towards more commercially successful or promising pipeline assets, potentially reflecting the competitive landscape or challenges in gene therapy commercialization within the hemophilia market. The focus on expanding VOXZOGO's indications and global reach aligns with a common strategy in rare disease companies to maximize the value of approved therapies. The acquisition of Inozyme Pharma indicates a continued inorganic growth strategy to bolster the pipeline.

Comparison to Industry Standards

• The 20%+ Y/Y revenue growth for PALYNZIQ and VOXZOGO is strong, particularly for established rare disease therapies, and compares favorably to typical pharmaceutical market growth rates.
• The divestment of ROCTAVIAN, a gene therapy, contrasts with other companies aggressively pursuing gene therapy commercialization (e.g., Pfizer, Sarepta, uniQure in hemophilia A), suggesting BioMarin may be exiting a segment where it sees less competitive advantage or higher commercialization hurdles.
• The IPR&D charge of $221 million from the Inozyme acquisition is a significant investment in pipeline expansion, common among biotech firms seeking to replenish or diversify their product offerings.
• The company's cash position of $2.0 billion and strong operating cash flow generation are robust for a biotech company, providing flexibility for R&D and potential future business development, often exceeding the cash reserves of smaller, development-stage biotechs.

Stakeholder Impact

• Shareholders: Mixed impact. Strong growth in key products and pipeline advancements are positive, but the significant GAAP loss and reduced non-GAAP guidance due to the IPR&D charge, along with the ROCTAVIAN divestment, could create short-term volatility. The long-term strategic focus on core assets and pipeline could be beneficial.
• Patients: Continued access to VOXZOGO and PALYNZIQ, with expanded indications and age groups planned. ROCTAVIAN patients will continue to receive support and monitoring, with the company seeking out-licensing to ensure continued access. New therapies in the pipeline offer future hope for unmet needs.
• Employees: Strategic portfolio focus and divestment of ROCTAVIAN could lead to some internal restructuring or reallocation of resources, though not explicitly detailed as layoffs.
• Customers (Healthcare Providers): Continued availability and support for existing therapies, with new data and expanded indications for VOXZOGO.
• Creditors: Strong operating cash flow and cash reserves suggest financial stability.

Next Steps

• Initiate dosing of children with achondroplasia in the registration-enabling Phase 2/3 study for BMN 333 in the first half of 2026.
• Expect VOXZOGO pivotal data for hypochondroplasia in the first half of 2026, followed by potential launch in 2027.
• Continue enrolling patients for four new VOXZOGO indications (idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency) under the CANOPY clinical program, with potential registration-enabling studies in 2027.
• Pursue approvals for PALYNZIQ in 12to 17-year-olds in the United States and Europe, with potential approval in 2026.
• Anticipate initial pivotal data readout for BMN 401 (ENPP1 deficiency) ENERGY 3 study in children ages 1-12 years in the first half of 2026, with potential launch in 2027.
• Share a clinical update for BMN 351 (Duchenne muscular dystrophy) 6 mg/kg and 9 mg/kg cohorts by year-end.
• Pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities, while continuing commercial availability in the U.S., Italy, and Germany until next steps are finalized.
• Implement initiatives to address slowing uptake of VOXZOGO in older children in the U.S.

Key Dates

Recommendation

The company demonstrates strong underlying performance in its core growth drivers, VOXZOGO and PALYNZIQ, and has a robust pipeline with multiple upcoming milestones. The increase in total revenue guidance is a positive signal of demand. However, the significant IPR&D charge from the Inozyme acquisition has materially impacted short-term profitability metrics, leading to a GAAP net loss and a substantial reduction in non-GAAP operating margin and EPS guidance. The decision to divest ROCTAVIAN, while a strategic portfolio adjustment, highlights challenges with a previously high-profile asset. Given the mixed financial signals—strong operational growth offset by a significant one-time charge and a strategic divestment—a "hold" recommendation is appropriate. Investors should monitor the integration of Inozyme, the progress of the pipeline, and the outcome of the ROCTAVIAN divestment for clearer long-term direction.

Keywords

BioMarin, BMRN, Q3 2025, earnings, financial results, VOXZOGO, PALYNZIQ, ROCTAVIAN, achondroplasia, hemophilia A, rare disease, gene therapy, enzyme therapy, IPR&D, Inozyme Pharma, BMN 333, BMN 401, ENPP1 deficiency, Duchenne muscular dystrophy, BMN 351, divestment, guidance